Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20975854 | 1.00 | EPAS1 (0.50) | EPAS1VEGFA | |
| SCHEMBL19870738 | 0.93 | EPAS1 (0.49) | EPAS1VEGFA | |
| SCHEMBL19870735 | 0.93 | EPAS1 (0.49) | EPAS1VEGFA | |
| SCHEMBL19870736 | 0.93 | EPAS1 (0.49) | EPAS1VEGFA | |
| SCHEMBL21362887 | 0.93 | EPAS1 (0.49) | EPAS1VEGFA | |
| SCHEMBL19870739 | 0.93 | EPAS1 (0.49) | EPAS1VEGFA | |
| SCHEMBL19872207 | 0.83 | EPAS1 (0.48) | EPAS1VEGFA | |
| SCHEMBL21362857 | 0.81 | EPAS1 (0.50) | EPAS1VEGFA | |
| SCHEMBL19870717 | 0.81 | EPAS1 (0.58) | EPAS1VEGFA | |
| SCHEMBL19870732 | 0.78 | EPAS1 (0.48) | EPAS1VEGFA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10278942-B2 | Compositions for use in treating pulmonary arterial hypertension | PELOTON THERAPEUTICS, INC. (US) | 2019-05-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10278942-B2 | Compositions for use in treating pulmonary arterial hypertension | MYLK, TNNI3, PDE2A | EPAS1 450/4885VEGFA 34/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.